|Fall 2023 Resident Seminars|
Join us on UHSP's campus for our Fall 2023 Resident Seminar Series!
Participants can choose from a variety of 45-minute live or virtual sessions, prepared by PGY1 and PGY2 pharmacy residents from the St. Louis metropolitan area. Pharmacists can earn a maximum of 2.25 of continuing pharmacy education credit per session, for a total of 6.75 CEUs for all three sessions.
Tuesday, October 10, from 1:00pm to 3:35pm
Wednesday, November 8, from 1:00 pm to 3:35 pm:
Thursday, December 14, from 1:00 pm to 3:35 pm: REGISTER FOR PARKING AND LEARN MORE HERE
|Distance CE Activities|
Expanded Role of Rivaroxaban in Patients with Diabetes and Coronary Artery Disease: Patients with diabetes mellitus (DM) are more likely to have cardiovascular (CV) disease and an increased thrombotic risk; therefore, aggressive management to prevent CV events is crucial. Join Dr. Ashley Lopez for a 45-minute presentation as she addresses emerging evidence on the potential use of dual pathway antithrombotic therapy with aspirin in combination with reduced-dose anticoagulant and stratify the clinical benefit in patients with diabetes mellitus and coronary artery disease.
The Utilization of Medications that Augment the Nitric Oxide Pathway in Heart Failure Patients: Join Dr. Brooke Jacobson as she examine the role of medications that augment the nitric oxide pathway in patients with heart failure with reduced ejection fraction. This presentation will begin by describing the background, etiology, and prevalence of heart failure followed by the pathophysiology. The pathophysiology in this presentation will specifically cover how the nitric oxide pathway is altered in patients with heart failure. Current guideline recommendations for optimizing heart failure medications will be reviewed. The presentation will then look at literature available for the nitric oxide augmenting agents. The trials that study the effectiveness of hydralazine/isosorbide (V-HeFT trials and the A-HeFT trial) will be reviewed and analyzed as well as the VICTORIA trial. The VICTORIA trial evaluates the efficacy of the newest agent in this drug class- vericiguat. The presentation will conclude with an evaluation of how these agents should be used in current practice. A treatment algorithm will be included to guide the decision on who should receive these agents.
A Closer Look at Episodic Migraine Prevention: Join Dr. Nicole Short for this 45-minute presentation where she discusses the characteristics of episodic migraine followed by an explanation of the mechanism of calcitonin gene-related peptide (CGRP) antagonists. An overview of current American Academy of Neurology recommendations and the European Headache Fede